EGAGenomicsILLUMINA, Illumina HiSeq 2000Otherhttps://ega-archive.org/studies/EGAS00001001572EGAEGA study EGAS00001001572whole genome sequencing data of genomic heterogeneity of multiple synchronous lung cancer.EGArestrictedbronchogenic lung adenocarcinoma, Lung Adenocarcinomas, Adenocarcinoma, nonsmall cell adenocarcinoma, Lung Adenocarcinoma, adenocarcinoma of the lung, Lung, lung adenocarcinoma, distinct, adenocarcinoma of lung, LUAD, non-small cell lung adenocarcinoma, whole genome, Adenocarcinomas, Genomes.DER/faint little ball, Malignant tumor of lung, Comparative Genome, Hunter Carpenter Macdonald syndrome, Antemortem Diagnosis, Materials, determination, Elp-B1, der, Elp-1, malignant tumor of lung, Errb1, malignant neoplasm of the lung, Tumor, Diagnosis, PIG61, Mutations, Background, ras, neurodegeneration with brain iron accumulation caused by mutation in PLA2G6, INAD, parenchyma of lung, epidermal growth factor-activated receptor activity, AI552599, symptoms, Impacts, Whole Transcriptome, Transcriptome Sequencing, ramiform, Environmental Impacts, d-egf-r, C-K-RAS, k-ras, Pulmonary cancer, rask2, treatment, Lung Cancer, Complete Exome Sequencing, alveolar cell carcinoma, Whole Transcriptome Sequencing, Lung Cancers, ramified, flb, Environmental Impact, Genome Hybridization, resistance to, Malignant neoplasm of lung, comparative genomic hybridization, Comparative Genomic Hybridizations, Therapies, 9030024J15Rik, D-EGFR, Malignancies, somatic mutation, Diagnose, NISBD2, Tumors, DER1, Therapy, screening, Lung cancer, Array-Based Comparative Genomic Hybridization, pulmo, Elp, early onset of peripheral gangrene, Wa5, l(2)09261, Hybridization, neuroaxonal dystrophy, Ki-ras, DEgfr, Comparative, Exome, lung parenchyma, Cancer of Lung, somatic, Hybridizations, CG10079, Diagnoses, torpedo/egfr, lymhpoid nodule, infantile neuroaxonal dystrophy/atypical neuroaxonal dystrophy, Benign, Postmortem, Screenings, wa2, cancer of lung, Examinations and Diagnoses, p21, Genetic Materials, Malignant lung tumor, malignant tumour of lung, Hunter-Carpenter-McDonald syndrome, Postmortem Diagnosis, neoplasms, Genetic Material, Diagnoses and Examination, egfr, Lung malignant tumors, Complete Transcriptome, Postmortem Diagnoses, malignant lung neoplasm, HD-33, El, Seitelberger disease, DER/EGFR, EGFR, EGfr, EgfR, adenocarcinoma of lung, Array Based Comparative Genomic Hybridization, susceptibility to, dEgfr, signs, Benign Neoplasms, DER flb, whole genome, Torpedo/Egfr, Treatments, Malignant Neoplasms, Degfr, response to tyrosine kinase inhibitor in, Comparative Genomic, pulmonary, Patient, RASK2, Material, DEGFR, Genome Hybridizations, l(2)57DEFa, l(2)05351, Whole Exome Sequencing, microarray, dEGFR, Cistron, root tubercle, DmHD-33, Cancer of the Lung, lung neoplasm, Phospholipase A2-associated neurodegeneration, Transcriptome Sequencings, KI-RAS, Cancer of the lung, INAD1, Lung, Genetic Backgrounds, D-Egf, Complete Exome, nodule, PLAN, C-erb, Neoplasms, malignant lung tumor, Kras2, NS3, lung cancer, Benign Neoplasm, mor1, Gene, PLA2G6 neurodegeneration with brain iron accumulation, mENA, EK2-6, Malignant, autosomal dominant, infantile, Array Comparative Genomic Hybridization, c-erbB, EGFr, Egfr, lung, Mass, Screening, Kras-2, torpedo/Egfr, EGF receptor activity, TOP, Egf-r, Antemortem, Pulmonary Cancer, neoplasm, Backgrounds, KRAS2, Pulmonary, KRAS1, p21B, WES, EGF-R, Complete, malignant tumour of the lung, Exome Sequencings, Genetic, Malignancy, K-RAS4B, K-RAS4A, LNCR, top, Torpedo/DER, chromosomal comparative genomic hybridization, Diagnoses and Examinations, Sequencing, top/flb, Neoplasias, Whole Exome, Lung Neoplasm, l(2)57EFa, Clients, malignant neoplasm of lung, Whole, heterogeneity, l(2)57Ea, Cancer, Elp-B1RB1, Antemortem Diagnoses, Pulmonary Neoplasms, KARAK syndrome, findings, Complete Exome Sequencings, Malignant Neoplasm, Genomic Hybridizations, TGF-alpha receptor activity, ERBB, dEGFR1, K-RAS2B, K-RAS2A, K-ras, Comparative Genome Hybridization, c-Ki-ras, Cistrons, Client, Examination and Diagnoses, Impact, Environmental, Exome Sequencing, disease management., epidermal growth factor receptor activity, DmelCG10079, Mass Screenings, chemical analysis, Neoplasm, malignant lung tumour, Nonsmall cell lung cancer, DER/top, AI929937, Comparative Genome Hybridizations, malignant tumor of the lung, NS, Complete Transcriptome Sequencing, neuroaxonal dystrophy presenting with neonatal dysmorphic features, top/DER, Pulmonary Neoplasm, patient, ERBB1, Cancers, wa-2, included, Egf, EFG-R, nonsmall cell lung cancer, Therapeutic, Errp, Genomic Hybridization, kras, Erbb, CFC2, Environments, Der, DER, protection against, Treatment, Lungs, Pulmonary Cancers, assay, transforming growth factor-alpha receptor activity, Neoplasia, DER/torpedo, HER1falseDistinct portrayal of lesions in synchronous multifocal lung adenocarcinoma revealed by genome sequencingDistinguishing multiple primary lung cancers in the synchronous multifocal intrapulmonary lesions has important significance on clinical staging and therapeutic decision. To investigate genomic aberration profiles, we applied whole genome and whole exome sequencing, and microarray-based comparative genomic hybridization on 15 intrapulmonary tumors derived from six patients with synchronous multifocal lung cancers having similar histological diagnosis. Any pair of intrapulmonary tumors in a single patient, which shared the identical genetic background and environment, showed an extinctive heterogeneity between each other. Phylogenetic relationship analysis indicated an independently branched evolution among all the tumors, suggesting they were multiple primary lung cancers. EGFR or KRAS mutations were found in 7 or 3 out of the 15 tumors, from 3 or 2 patients, respectively. Somatic mutational heterogeneity of these two genes in a single patient was also observed. Our analysis indicates genomic aberration profiling is valuable for identification of multiple primary lung cancer, especially when high histopathological concordance was observed between lesions. We also suggest a thoroughly molecular diagnosis against therapeutic target genes should be taken for each accessible nodule before making a plan for adjuvant therapy.2017-07-27 14:50:52EGAS000010015729606EGAD00001003458EGAC00001000177